FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205125475> ?p ?o ?g. }

• W4205125475 abstract "Background: OnabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) target different migraine pathways, therefore, combination treatment may provide additional effectiveness for the preventive treatment of chronic migraine (CM) than either treatment alone. The objective of this study was to collect real-world data to improve the understanding of the safety, tolerability, and effectiveness of adding a CGRP mAb to onabotulinumtoxinA treatment for the preventive treatment of CM. Methods: This was a retrospective, longitudinal study conducted using data extracted from a single clinical site's electronic medical records (EMR) of adult patients (≥18 years) with CM treated with ≥2 consecutive cycles of onabotulinumtoxinA before ≥1 month of continuous onabotulinumtoxinA and CGRP mAb (erenumab, fremanezumab, or galcanezumab) combination treatment. Safety was evaluated by the rate of adverse events (AE) and serious adverse events (SAE). The proportion of patients who discontinued either onabotulinumtoxinA, a CGRP mAb, or combination treatment, and the reason for discontinuation, if available, was collected. The effectiveness of combination preventive treatment was assessed by the reduction in monthly headache days (MHD). Outcome data were extracted from EMR at the first CGRP mAb prescription (index) and up to four assessments at ~3, 6, 9, and 12 months post-index. The final analyses were based on measures consistently reported in the EMR. Results: EMR were collected for 192 patients, of which 148 met eligibility criteria and were included for analysis. Erenumab was prescribed to 56.7% of patients, fremanezumab to 42.6%, and galcanezumab to 0.7%. Mean (standard deviation [SD]) MHD were 20.4 (6.6) prior to onabotulinumtoxinA treatment and 14.0 (6.9) prior to the addition of a CGRP mAb (baseline). After real-world addition of a CGRP mAb, there were significant reductions in MHD at the first assessment (~3 months) (mean -2.6 days/month, 95% CI -3.7, -1.4) and at all subsequent visits. After ~12 months of continuous combination treatment, MHD were reduced by 4.6 days/month (95% CI -6.7, -2.5) and 34.9% of patients achieved ≥50% MHD reduction from index. AEs were reported by 18 patients (12.2%), with the most common being constipation (n = 8, 5.4% [onabotulinumtoxinA plus erenumab only]) and injection site reactions (n = 5, 3.4%). No SAEs were reported. Overall, 90 patients (60.8%) discontinued one or both treatments. The most common reason for discontinuing either treatment was lack of insurance coverage (40%); few (~14%) patients discontinued a CGRP mAb and none discontinued onabotulinumtoxinA due to safety/tolerability. Conclusion: In this real-world study, onabotulinumtoxinA was effective at reducing MHD and the addition of a CGRP mAb was safe, well-tolerated and associated with incremental and clinically meaningful reductions in MHD for those who stayed on the combination treatment. No new safety signals were identified. Of those who discontinued, the majority reported lack of insurance coverage as a reason. Prospective real-world and controlled trials are needed to further evaluate the safety and potential benefits of this combination treatment paradigm for people with CM." @default.
• W4205125475 created "2022-01-25" @default.
• W4205125475 creator A5002925030 @default.
• W4205125475 creator A5015730759 @default.
• W4205125475 creator A5050943980 @default.
• W4205125475 creator A5063941902 @default.
• W4205125475 creator A5065645622 @default.
• W4205125475 creator A5072564621 @default.
• W4205125475 date "2022-01-06" @default.
• W4205125475 modified "2023-09-30" @default.
• W4205125475 title "Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine" @default.
• W4205125475 cites W1982183874 @default.
• W4205125475 cites W2007410119 @default.
• W4205125475 cites W2061867043 @default.
• W4205125475 cites W2073160193 @default.
• W4205125475 cites W2086228377 @default.
• W4205125475 cites W2094473459 @default.
• W4205125475 cites W2106177437 @default.
• W4205125475 cites W2115337076 @default.
• W4205125475 cites W2134578184 @default.
• W4205125475 cites W2260435540 @default.
• W4205125475 cites W2325770952 @default.
• W4205125475 cites W2332116348 @default.
• W4205125475 cites W2760684802 @default.
• W4205125475 cites W2768357559 @default.
• W4205125475 cites W2786230526 @default.
• W4205125475 cites W2801085490 @default.
• W4205125475 cites W2801341258 @default.
• W4205125475 cites W2803715733 @default.
• W4205125475 cites W2901687990 @default.
• W4205125475 cites W2917635262 @default.
• W4205125475 cites W2929053468 @default.
• W4205125475 cites W2935967254 @default.
• W4205125475 cites W2968888063 @default.
• W4205125475 cites W2970373125 @default.
• W4205125475 cites W2977140154 @default.
• W4205125475 cites W3007053288 @default.
• W4205125475 cites W3013502865 @default.
• W4205125475 cites W3021146107 @default.
• W4205125475 cites W3026778315 @default.
• W4205125475 cites W3040027196 @default.
• W4205125475 cites W3046431585 @default.
• W4205125475 cites W3096991256 @default.
• W4205125475 cites W3109911524 @default.
• W4205125475 cites W3135078565 @default.
• W4205125475 cites W3154454412 @default.
• W4205125475 cites W4230120862 @default.
• W4205125475 cites W4255987705 @default.
• W4205125475 doi "https://doi.org/10.3389/fneur.2021.788159" @default.
• W4205125475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35069416" @default.
• W4205125475 hasPublicationYear "2022" @default.
• W4205125475 type Work @default.
• W4205125475 citedByCount "17" @default.
• W4205125475 countsByYear W42051254752022 @default.
• W4205125475 countsByYear W42051254752023 @default.
• W4205125475 crossrefType "journal-article" @default.
• W4205125475 hasAuthorship W4205125475A5002925030 @default.
• W4205125475 hasAuthorship W4205125475A5015730759 @default.
• W4205125475 hasAuthorship W4205125475A5050943980 @default.
• W4205125475 hasAuthorship W4205125475A5063941902 @default.
• W4205125475 hasAuthorship W4205125475A5065645622 @default.
• W4205125475 hasAuthorship W4205125475A5072564621 @default.
• W4205125475 hasBestOaLocation W42051254751 @default.
• W4205125475 hasConcept C118303440 @default.
• W4205125475 hasConcept C126322002 @default.
• W4205125475 hasConcept C163170386 @default.
• W4205125475 hasConcept C170493617 @default.
• W4205125475 hasConcept C197934379 @default.
• W4205125475 hasConcept C2778375690 @default.
• W4205125475 hasConcept C2778541695 @default.
• W4205125475 hasConcept C2778715236 @default.
• W4205125475 hasConcept C2910587157 @default.
• W4205125475 hasConcept C71924100 @default.
• W4205125475 hasConceptScore W4205125475C118303440 @default.
• W4205125475 hasConceptScore W4205125475C126322002 @default.
• W4205125475 hasConceptScore W4205125475C163170386 @default.
• W4205125475 hasConceptScore W4205125475C170493617 @default.
• W4205125475 hasConceptScore W4205125475C197934379 @default.
• W4205125475 hasConceptScore W4205125475C2778375690 @default.
• W4205125475 hasConceptScore W4205125475C2778541695 @default.
• W4205125475 hasConceptScore W4205125475C2778715236 @default.
• W4205125475 hasConceptScore W4205125475C2910587157 @default.
• W4205125475 hasConceptScore W4205125475C71924100 @default.
• W4205125475 hasLocation W42051254751 @default.
• W4205125475 hasLocation W42051254752 @default.
• W4205125475 hasLocation W42051254753 @default.
• W4205125475 hasLocation W42051254754 @default.
• W4205125475 hasOpenAccess W4205125475 @default.
• W4205125475 hasPrimaryLocation W42051254751 @default.
• W4205125475 hasRelatedWork W2955283194 @default.
• W4205125475 hasRelatedWork W3011397600 @default.
• W4205125475 hasRelatedWork W3038802552 @default.
• W4205125475 hasRelatedWork W3195126616 @default.
• W4205125475 hasRelatedWork W3204978772 @default.
• W4205125475 hasRelatedWork W3206572053 @default.
• W4205125475 hasRelatedWork W4200628345 @default.
• W4205125475 hasRelatedWork W4288077664 @default.
• W4205125475 hasRelatedWork W4367303390 @default.
• W4205125475 hasRelatedWork W4367721089 @default.
• W4205125475 hasVolume "12" @default.

• next